Registry for Exablate Neuro treatment in Parkinson's Disease
Official title: A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
Run by InSightec · NCT05539196 · Data updated 2026-11-12
This study is tracking 60 people with advanced Parkinson's Disease to see how well a new treatment using the Exablate Neuro device works for those who haven't had success with medications.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Years to 99 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | InSightec Industry-sponsored |
| Locations | 5 sites (Baltimore, Maryland and 4 other locations) |
| Status | Recruiting |
| Started | January 23, 2023 |
| Main results expected | July 31, 2029 |
| Study ends | July 31, 2029 |
| Registry record updated | March 20, 2026 |
| Trial ID | NCT05539196 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men and women aged 30 years and older who are undergoing a planned Exablate procedure for their Parkinson's Disease.
✕Probably not a fit
Patients who do not agree to participate or are unlikely to complete the registry requirements will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter, international observational registry that aims to collect data on patients undergoing unilateral pallidotomy using the Exablate Neuro device for advanced Parkinson's Disease with medication-refractory motor complications. The registry will enroll 60 subjects across approximately 10 centers worldwide and will follow participants for 5 years, with assessments at baseline, 3, 6, and 12 months, and annually thereafter. Data collected will include adverse events, medication usage, and various patient-reported outcomes to evaluate the treatment's effectiveness and safety.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into the long-term safety and effectiveness of the Exablate Neuro treatment for patients with advanced Parkinson's Disease.
How similar studies have gone: Other studies involving similar approaches to treating Parkinson's Disease have shown promise, but this registry specifically focuses on the Exablate Neuro device post-approval.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women, age 30 years and older. * Subject undergoing a planned an Exablate procedure for their Parkinson's Disease with Motor Complications per local institution standard of care. * Subject is willing to cooperate with the Registry requirements including compliance with the regimen and completion of all Registry visits. * Subject has signed and received a copy of the approved informed consent form. Exclusion Criteria: * Subject does not agree to participate or is unlikely to participate for the entirety of the Registry.
Where it's running
-
University of Maryland, Baltimore
Baltimore, Maryland, United States Recruiting -
Weill Cornell Medicine
New York, New York, United States Recruiting -
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting -
University of Texas Southwestern Medical Center
Dallas, Texas, United States Recruiting -
Ohnishi Neurological Center
Akashi, Hyōgo, Japan Recruiting
Study contacts
- Study coordinator: Kingsley Nwaogu
- Email: clinicalresearchquestions@insightec.com
- Phone: 2143048265
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mindfulness program for people with Parkinson's and their caregivers
This study tests whether a mindfulness program can help people with Parkinson's and their caregivers feel better emotionally and improve their relationship.
-
Ginger as a Modifier of Ghrelin Levels in Parkinson’s Disease and REM Sleep Behavior Disorder
This study tests whether ginger capsules can raise ghrelin levels in people with Parkinson’s disease, REM sleep behavior disorder, and healthy controls.
-
Newborn screening for AADC deficiency in Liguria
This project tests a newborn screening approach for AADC deficiency in Liguria to see if many newborns can be identified early and referred for care.
-
Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment
This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.
-
Mental imagery with self-regulation to help daily activities in Parkinson's disease
This study tests whether a six-week program of mental imagery combined with self-regulation can help people with Parkinson’s perform daily activities better than standard learning or exercise.
-
Real-world experiences of Inbrija for Parkinson's OFF episodes
This study looks at how people with Parkinson’s who use Inbrija for OFF episodes feel and function in daily life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.